Influenza News and Research

Latest Influenza News and Research

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Massive mismanagement leads to catastrophic decline in freshwater biodiversity

The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science.

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

Health care workers raise troubling concern about H1N1 and seasonal flu vaccines

Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).

13 Oct 2009

Cox's initiative to safeguard the community at-large

Recognized as a leader in serving its customers with state-of-the-art cable, broadband and entertainment services, Cox will soon broaden its local impact by safeguarding the community at-large. On October 30, 2009, Cox will be the first and only private corporation to operate as one of three Orange County locations to conduct an Orange County Health Care Agency (OCHCA) Point-Of-Dispensing (POD) at its Rancho Santa Margarita headquarters.

13 Oct 2009

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized companies, today announced that it will cover 100% of the cost associated with the administration of the H1N1 vaccine for employees and their eligible dependents enrolled in a fully-insured Guardian medical plan.

13 Oct 2009

Educational video on seasonal and H1N1 vaccines development

Will a four-minute educational video about a team of Air Force researchers investigating the H1N1 influenza virus go "viral" with middle- and high-school students?

12 Oct 2009

Fully insured members of AvMed Health to receive coverage for H1N1 flu administration fees

AvMed Health Plans announced that it will cover H1N1 flu administration fees for all of its fully insured members. Co-pays, co-insurance and deductibles will not apply for administration of the H1N1 vaccine even if they have a benefit plan that does not include immunizations.

12 Oct 2009

H1N1 illness in young Mexican patients associated with severe acute respiratory distress syndrome

Critical illness from 2009 influenza A(H1N1) in Mexico occurred among young patients, was associated with severe acute respiratory distress syndrome and shock, and had a fatality rate of about 40 percent, according to a study to appear in the November 4 issue of JAMA.

12 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Public forum and scientific workshop on women's health issues

The Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital will host a public forum and scientific workshop Oct. 14 to 16 to discuss emerging issues of importance for the National Institutes of Health (NIH) for women's health research in the coming decade.

12 Oct 2009

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Wal-Mart Stores to offer Tamiflu oral suspension in liquid form for children and elderly

Wal-Mart Stores, Inc. announced today that more than 4,000 Walmart and Sam's Club pharmacies nationwide will address the national shortage of Tamiflu® oral suspension by converting the capsule to liquid form.

12 Oct 2009

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.

12 Oct 2009

A three-month study reveals the impact of swine flu on the health of the general public in Australia and New Zealand

A comprehensive study has revealed, for the first time, the impact of swine flu on the health of the general public in Australia and New Zealand.

9 Oct 2009

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

Solvay Pharmaceuticals, Inc. announced that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI).

9 Oct 2009

MedaSorb Technologies raises $1.3 million to help finance ongoing European Sepsis Trial

MedaSorb Technologies Corporation and its wholly-owned subsidiary CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant attached to the Series B financing completed in August 2008. Dr. Phillip Chan, Chief Executive Officer, stated, "We are pleased to have the continued support of our existing investors.

9 Oct 2009

Verichip Corporation's H1N1 virus triage detection system to feature in Fox News

VeriChip Corporation has announced that the Company is scheduled to be featured on the Glenn Beck show on Fox News today, October 8, 2009 during the 5 p.m. hour. Glenn Beck intends to dedicate today's show to the H1N1 virus and will feature VeriChip, its Health Link personal health record and its H1N1 virus triage detection system currently being developed with partner RECEPTORS LLC, as part of the show.

9 Oct 2009

LeVOCC air purification system destroys the PR8 strain of the H1N1 virus

LeVOCC, Inc. today announced that independent laboratory testing has conclusively demonstrated that the LeVOCCTM air purification system successfully destroys a strain of the H1N1 virus. Testing was conducted using the Puerto Rico 8 (PR8) strain of the H1N1 virus. This strain is an influenza A H1N1 seasonal strain and is a valid representative of all H1N1 strains.

9 Oct 2009

Influenza News and Research

Latest Influenza News and Research

Johnson & Johnson announces financial results for the third quarter of 2009

Massive mismanagement leads to catastrophic decline in freshwater biodiversity

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Health care workers raise troubling concern about H1N1 and seasonal flu vaccines

Cox's initiative to safeguard the community at-large

Fully-insured members of Guardian to receive 100% coverage of the administrative cost of H1N1 vaccine

Educational video on seasonal and H1N1 vaccines development

Fully insured members of AvMed Health to receive coverage for H1N1 flu administration fees

H1N1 illness in young Mexican patients associated with severe acute respiratory distress syndrome

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

Public forum and scientific workshop on women's health issues

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

Presentations on efficacy of interferon to combat influenza

Wal-Mart Stores to offer Tamiflu oral suspension in liquid form for children and elderly

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

A three-month study reveals the impact of swine flu on the health of the general public in Australia and New Zealand

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

MedaSorb Technologies raises $1.3 million to help finance ongoing European Sepsis Trial

Verichip Corporation's H1N1 virus triage detection system to feature in Fox News

LeVOCC air purification system destroys the PR8 strain of the H1N1 virus

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Influenza News and Research

Latest Influenza News and Research

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in